AiM  Vol.5 No.4 , April 2015
Study of Serotypes, Susceptibility to Macrolide and Virulence and Resistance Molecular Profiles in Invasive Strains of Streptococcus agalactiae in Two Argentine Provinces
A study of invasive strains of Streptococcus agalactiae (GBS) from Cordoba and Misiones, Argentina; was conducted to determine serotypes, the susceptibility to macrolides and molecular profiles of virulence and resistance. We studied 17 strains, recovered from cerebrospinal fluid, blood and cellulite and, a strain of trophoblastic remnants from Misiones. The serotypes were determined by agglutination with sera and phenotypes of resistance to macrolide-lincosamide-streptogramin B (MLSB), were determined with the double-disk test (D-test). The confirmation was performed by E-test by ERI and CLI respectively that determined the minimum inhibitory concentration (MIC). Results were interpreted as recommended by the Clinical and Laboratory Standards Institute (CLSI) 2013. Resistance genes: ermB, ermTR and mefA and the virulence genes: bac, bca, rib, lmb, hylB, scpB, fbsA, fbsB and cylB were investigated by conventional PCR. Serotype III (50%) and Ia (50%) were detected in Cordoba. One strain showed cMLSB phenotype, confirmed by MIC. The same strains showed a resistance gene ermB. All studied virulence genes were detected in 100% of these strains. In Misiones, serotypes were III (72.7%), Ia (18.2%) and Ib (9.1%). All strains were susceptible to CLI and ERI by D-test, confirmed by MIC. None of the strains showed resistance genes. Virulence genes bca, rib, hylB, lmb, fbsA, fbsB and cylB were detected in 100% of the strains, bac in 81.8% and scpB in 90.9%. Our results are in accordance with international data, associating higher frequency of serotype III of invasive neonatal disease followed by Ia. The presence of serotype Ib could indicate a regional difference for Misiones. We highlight the macrolides susceptibility in strains of Misiones and consistency in the results for D-test, MIC and PCR for the single strain resistant phenotype cMLSB from Cordoba. The virulence genes studied were presented with high frequency as expected for invasive strains.

Cite this paper
Laczeski, M. , Novosak, M. , Giolito, R. , Littvik, A. , Paván, J. , Villalba, V. and Vergara, M. (2015) Study of Serotypes, Susceptibility to Macrolide and Virulence and Resistance Molecular Profiles in Invasive Strains of Streptococcus agalactiae in Two Argentine Provinces. Advances in Microbiology, 5, 230-243. doi: 10.4236/aim.2015.54021.
[1]   Tara, C. and Smith, T.C. (2007) Deadly Diseases and Epidemics. Chelsea House, New York, 57-58.

[2]   Heath, P. and Schuchat, A. (2007) Perinatal Group B Streptococcal Disease. Best Practice & Research Clinical Obstetrics and Gynaecology, 21, 411-424.

[3]   Lindhal, G., Stalhammar-Carlemalm, M. and Areschoug, T. (2005) Surface Proteins of Streptococcus agalactiae and Related Proteins in Other Bacterial Pathogens. Revista Argentina De Microbiologia, 18, 102-127.

[4]   Tamariz Ortiz, J.H., Obregon Calero, M., Jara Aguirre, J.C., Diaz Herrera, J. and Jefferson Cortes, L. (2004) Colonizacion vaginal y anorrectal por Streptococcus agalactiae en gestantes de los Hospitales Nacionales Cayetano Heredia y Arzobispo Loayza. Revista Medica Herediana, 15, 144-150.

[5]   Garcia, S.D., Eiseth, M.C., Lazzo, M.J., Copolillo, E., Barata, A.D., De Torres, R. and Vay, C.A. (2003) Group B Streptococcus Carriers among Pregnant Women. Revista Argentina De Microbiologia, 35, 183-187.

[6]   Oviedo, P., Pegels, E., Laczeski, M., Quiroga, M. and Vergara, M. (2013) Phenotypic and Genotypic Characterization of Streptococcus agalactiae in Pregnant Women. First Study in a Province of Argentina. Brazilian Journal of Microbiology, 44, 253-258.

[7]   Cruz, M.O., Doren, A.V.,Tapia, J.L. and Abarzua, F.C. (2008) Sepsis Neonatal por Streptococcus Grupo B. Revista Chilena de Pediatria, 79, 462-470.

[8]   Centers for Disease Control and Prevention (2010) Prevention of Perinatal Group B: Revised Guidelines from CDC. MMWR Recommendations and Reports, 59, 1-31.

[9]   Morin, C., White, K. and Schuchat, A. (2005) Perinatal Group B Streptococcal Disease Prevention, Minnesota. Emerging Infectious Diseases, 11, 1467-1469.

[10]   Ley Nacional No 26.369 (2008).

[11]   Udo, E.E., Boswihi, S.S. and Al-Sweih, N. (2013) Genotypes and Virulence Genes in Group B Streptococcus Isolated in the Maternity Hospital, Kuwait. Medical Principles and Practice, 22, 453-457.

[12]   Edwards, M.S. and Baker, C.J. (2006) Streptococcus agalactiae (Estreptococos del grupo B). In: Bennett, J.E., Dolin, R. and Mandell, G.L., Eds., Enfermedades Infecciosas, Principios y PrActicas, Elsevier Espana S.A., Madrid, 2423-2434.

[13]   Dutra, V.G., Alves, V.M., Olendzki, A.N., Dias, C.A., De Bastos, A.F., Santos, G.O., et al.(2014) Streptococcus agalactiae in Brazil: Serotype Distribution, Virulence Determinants and Antimicrobial Susceptibility. BMC Infectious Diseases, 14, 323-330.

[14]   Wang, Z., Guo, C., Xu, Y., Liu, G., Lu, C. and Liu, Y. (2014) Two Novel Functions of Hyaluronidase from Streptococcus agalactiae Are Enhanced Intracellular Survival and Inhibition of Proinflammatory Cytokine Expression. Infection and Immunity, 82, 2615-2625.

[15]   Bohnsack, J., Takahashi, S., Detrick, S., Pelinka, L., Hammitt, L., Aly, A., Whiting, A. and Adderson, E. (2001) Phylogenetic Classification of Serotype III Group B Streptococci on the Basis of hylB Gene Analysis and DNA Sequences Specific to Restriction Digest Pattern Type III-3. The Journal Infectious Diseases, 183, 1694-1697.

[16]   Zhang, Y., Shao, Z., Wang, J., Wang, L., Li, X., Wang, C., Tang, J. and Pan, X. (2014) Prevalent Distribution and Conservation of Streptococcus suis Lmb Protein and Its Protective Capacity against the Chinese Highly Virulent Strain Infection. Microbiological Research, 169, 395-401.

[17]   Landwehr-Kenzel, S. and Henneke, P. (2014) Interaction of Streptococcus agalactiae and Cellular Innate Immunity in Colonization and Disease. Frontiers in Immunology, 5, 519.

[18]   Manning, S.D., Ki, M., Marrs, C.F., Kugeler, K.J., Borchardt, S.M., Baker, C.J., et al. (2006) The Frequency of Genes Encoding Three Putative Group B Streptococcal Virulence Factors among Invasive and Colonizing Isolates. BMC Infectious Diseases, 6, 116.

[19]   Schubert, A., Zakikhany, K., Pietrocola, G., Meinke, A., Speziale, P. and Eikmanns, B.J. (2004) The Fibrinogen Receptor FbsA Promotes Adherence of Streptococcus agalactiae to Human Epithelial Cells. Infection and Immunity, 72, 6197-6205.

[20]   Doran, K.S. and Nizet, V. (2004) Molecular Pathogenesis of Neonatal Group B Streptococcal Infection: No Longer in Its Infancy. Molecular Microbiology, 54, 23-31.

[21]   Meinke, A.L., Senn, B.M., Visram, Z., Henics, T.Z., Minh, D.B. and Schuler, W. (2010) Immunological Fingerprinting on Group B Streptococci: From Circulating Human Antibodies to Protective Antigens. Vaccine, 28, 6997-7008.

[22]   Tenenbaum, T., Bloier, C., Adam, R., Reinscheid, D.J. and Schroten, H. (2005) Adherence to and Invasion of Human Brain Microvascular Endothelial Cells Are Promoted by Fibrinogen-Binding Protein FbsA of Streptococcus agalactiae. Infection and Immunity, 73, 4404-4409.

[23]   Rivera, J., Vannakambadi, G., Hook, M. and Speziale, P. (2007) Fibrinogen-Binding Proteins of Gram-Positive Bacteria. Thrombosis and Haemostasis, 98, 503-511.

[24]   Dramsi, S., Morello, E., Poyart, C. and Trieu-Cuot, P. (2012) Epidemiologically and Clinically Relevant Group B Streptococcus Isolates Do Not Bind Collagen but Display Enhanced Binding to Human Fibrinogen. Microbes and Infection, 14, 1044-1048.

[25]   Schubert, A., Zakikhany, K., Schreiner, M., Frank, R., Spellerberg, B., et al. (2002) A Fibrinogen Receptor from Group B Streptococcus Interacts with Fibrinogen by Repetitive Units with Novel Ligand Binding Sites. Molecular Microbiology, 46, 557-569.

[26]   Gutekunst, H., Eikmanns, B.J. and Reinscheid, D.J. (2004) The Novel Fibrinogen-Binding Protein FbsB Promotes Streptococcus agalactiae Invasion into Epithelial Cells. Infection and Immunity, 72, 3495-3504.

[27]   Al Safadi, R., Mereghetti, L., Salloum, M., Lartigue, M.F., Virlogeux-Payant, I., et al. (2011) Two-Component System RgfA/C Activates the FbsB Gene Encoding Major Fibrinogen-Binding Protein in Highly Virulent CC17 Clone Group B Streptococcus. PLoS ONE, 6, e14658.

[28]   Rosenau, A., Martins, K., Amor, S., Gannier, F., Lanotte, P., et al. (2007) Evaluation of the Ability of Streptococcus agalactiae Strains Isolated from Genital and Neonatal Specimens to Bind to Human Fibrinogen and Correlation with Characteristics of the FbsA and FbsB Genes. Infection and Immunity, 75, 1310-1317.

[29]   Madhi, S.A., Dangor, Z., Heath, P.T., Schrag, S., Izu, A., Sobanjo-Ter Meulen, A., et al. (2013) Considerations for a Phase-III Trial to Evaluate a Group B Streptococcus Polysaccharide-Protein Conjugate Vaccine in Pregnant Women for the Prevention of Early- and Late-Onset Invasive Disease in Young-Infants. Vaccine, 31, D52-D57.

[30]   Lancefield, R.C. (1933) A Serological Differentiation of Human and Other Groups of Hemolytic Streptococci. Journal of Experimental Medicine, 57, 571-595.

[31]   Burns, G. and Plumb, J. (2013) GBS Public Awareness, Advocacy, and Prevention: What’s Working, What’s Not and Why We Need a Maternal GBS Vaccine. Vaccine, 31, D58-D65.

[32]   Chen, V.L., Avci, F.Y. and Kasper, D.L. (2013) A Maternal Vaccine against Group B Streptococcus: Past, Present, and Future. Vaccine, 31, D13-D19.

[33]   Persson, E., Berg, S., Bevanger, L., Bergh, K., Valso-Lyng, R. and Tollfors, B. (2008) Characterisation of Invasive Group B Streptococci Based on Investigation of Surface Proteins and Genes Encoding Surface Proteins. Clinical Microbiology and Infection, 14, 66-73.

[34]   Castor, M.L., Whitney, C.G., Como-Sabetti, K., Facklam, R.R., Ferrieri, P., Bartkus, J.M., et al. (2008) Antibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates. Infectious Diseases in Obstetrics and Gynecology, 2008, Article ID: 727505.

[35]   Campelo, F.A., Pedrosa, A.C., Antunez, I.A. and Capuz, B.L. (2012) Phenotypes and Mechanisms of Resistance to Macrolides and Lincosamides in Streptococcus agalactiae Isolates with Clinical Significance in an Eight-Year Period (2002-2010). Revista Espanola de Quimioterapia, 25, 42-46.

[36]   Famiglietti, A., Quinteros, M., Pedrari, S., Corso, A., Marin, M., Nicola, F., et al. (2004) Actualizacion del Consenso Sobre las Pruebas de Sensibilidad a los Antimicrobianos en Cocos Grampositivos. SADEBAC-AAM, Buenos Aires.

[37]   Mensa, J., Garcia-VAzquez, E. and Vila, J. (2003) Macrolidos, cetolidos y estreptograminas. Enfermedades Infecciosas y Microbiologia Clinica, 21, 200-208.

[38]   Feng-Ying, C., Parvin, H., Leonard, E., Joseph, B., et al. (2000) Antibiotic Susceptibility Profiles for Group B Streptococci Isolated from Neonates, 1995-1998. Clinical Infectious Diseases, 31, 76-79.

[39]   CLSI (2013) Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. Clinical and Laboratory Standards Institute, 33, M100S23.

[40]   Tamariz Ortiz, J., Cruz Quintanilla, J., Atencia Porras, A., Figueroa Tataje, J., Horna Quintana, G. and Guerra Allison, H. (2009) Resistencia a Clindamicina inducida por Eritromicina en Staphylococcus aureus aislados de tres hospitales de Lima, Peru. Acta Medica Peruana, 26, 12-16.

[41]   Sambrook, J. and Rusell, D.W. (2001) Molecular Cloning: A Laboratory Manual. 3rd Edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, New York, 1-3.

[42]   Cariaga Martinez, A.E and Zapata, P.D. (2007) Protocolos de extraccion de ADN. In: Zapata, P.D. and Cariaga Martinez, A.E., Eds., El laboratorio de biologia molecular, Edicion ampliada, Editorial Universitaria de Misiones, Misiones, 23-39.

[43]   Edwards, M.S. (2008) Group B Streptococcal Conjugate Vaccine: A Timely Concept for Which the Time Has Come. Human Vaccines, 4, 444-448.

[44]   Pettersson, K. (2007) Perinatal Infection with Group B Streptococci. Seminars in Fetal and Neonatal Medicine, 12, 193-197.

[45]   Poyart, C., Reglier-Poupet, H., Tazi, A., Billoet, A., Dmytruk, N., Bidet, P., et al. (2008) Invasive Group B Streptococcal Infections in Infants, France. Emerging Infectious Diseases, 14, 1647-1649.

[46]   Juncosa-Morros, T., Guardia-Llobet, C., Bosch-Mestres, J., Dopico-Ponte, E., Sanfeliu-Sala, I., Sierra-Soler, M., et al. (2014) Streptococcus Agalactiae Late-Onset Neonatal Infections in Barcelona (1996-2010). Enfermedades Infecciosas y Microbiologia Clinica, 32, 574-578.

[47]   Liebana-Martos Mdel, C., Cabrera-Alavargonzalez, J., Rodriguez-Granger, J., Miranda-Casas, C., Sampedro-Martinez, A., Gutierrez-FernAndez, J., et al. (2014) Serotypes and Antibiotic Resistance Patterns in Beta-Hemolytic Streptococcus agalactiae Isolates in Colonized Mothers and Newborns with Invasive Disease. Enfermedades Infecciosas y Microbiologia Clinica, 33, 84-88.

[48]   Edmond, K.M., Kortsalioudaki, C., Scott, S., Schrag, S.J., Zaidi, A.K., Cousens, S., et al. (2014) Group B Streptococcal Disease in Infants Aged Younger than 3 Months: Systematic Review and Meta-Analysis. The Lancet, 379, 547-556.

[49]   Brzychczy-Wloch, M., Gosiewski, T. and Bulanda, M. (2014) Multilocus Sequence Types of Invasive and Colonizing Neonatal Group B Streptococci in Poland. Medical Principles and Practice, 23, 323-330.

[50]   Martins, E.R., Melo-Cristino, J. and Ramirez, M. (2012) Dominance of Serotype Ia among Group B Streptococci Causing Invasive Infections in Nonpregnant Adults in Portugal. Journal of Clinical Microbiology, 50, 1219-1227.

[51]   Eskandarian, N., Ismail, Z., Neela, V., Van Belkum, A., Desa, M. and Amin Nordin, S. (2014) Antimicrobial Susceptibility Profiles, Serotype Distribution and Virulence Determinants among Invasive, Non-Invasive and Colonizing Streptococcus agalactiae (Group B Streptococcus) from Malaysian Patients. European Journal of Clinical Microbiology & Infectious Diseases, 34, 579-584.

[52]   Fernandez, M., Hickman, M. and Baker, C. (1998) Antimicrobial Susceptibilities of Group B Streptococci Isolated between 1992 and 1996 from Patients with Bacteremia or Meningitis. Antimicrobial Agents and Chemotherapy, 42, 1517-1519.

[53]   Ko, W., Lee, H., Wang, L., Lee, C., Liu, A. and Wu, J. (2001) Serotyping and Antimicrobial Susceptibility of Group B Streptococcus an Eight Years Period in Southern Taiwan. European Journal of Clinical Microbiology & Infectious Diseases, 20, 334-339.

[54]   Matsubaraa, K., Nishiyamab, Y., Katayamac, K., Yamamotod, G., Sugiyamae, M., Muraif, T., et al. (2001) Change of Antimicrobial Susceptibility of Group B Streptococci over 15 Years in Japan. Journal of Antimicrobial Chemotherapy, 48, 579-582.

[55]   Brimil, N., Barthell, E., Heindrichs, U., Kuhn, M., Lütticken, R. and Spellerberg, B. (2006) Epidemiology of Streptococcus agalactiae Colonization in Germany. International Journal of Medical Microbiology, 296, 39-44.

[56]   Keil, A., Laczeski, M., Oviedo, P., Pegels, E., Quiroga, M., Fonseca, M. and Vergara, M. (2010) Deteccion del gen rib en cepas invasivas y colonizantes de Streptococcus agalactiae en Misiones. Revista de Ciencia y Tecnologia, 14, 25-28.

[57]   Johri, A.K., Paoletti, L.C., Glaser, P., Dua, M., Sharma, P.K., Grandi, G., et al. (2006) Group B Streptococcus: Global Incidence and Vaccine Development. Nature Reviews Microbiology, 4, 932-942.

[58]   Campelo, F., Pedrosa, A., Antunez, I. and Capuz, B. (2012) Phenotypes and Mechanisms of Resistance to Macrolides and Lincosamides in Streptococcus agalactiae Isolates with Clinical Significance in an Eight-Year Period (2002-2010). Revista Espanola de Quimioterapia, 25, 42-46.

[59]   Hsueh, P.R., Teng, L.J., Lee, L.N., Ho, S.W., Yang, P.C. and Luh, K.T. (2001) High Incidence of Erythromycin Resistance among Clinical Isolates of Streptococcus agalactiae in Taiwan. Antimicrobial Agents and Chemotherapy, 41, 3205-3208.


[61]   Leclercq, R. and Courvalin, P. (1991) Bacterial Resistance to Macrolide, Lincosamide, and Streptogramin Antibiotics by Target Modification. Antimicrobial Agents and Chemotherapy, 35, 1267-1272.

[62]   Dela Cruz, W., Richardson, J., Broestle, J., Thornton, J. and Danaher, P. (2007) Rapid Determination of Macrolide and Lincosamide Resistance in Group B Streptococcus Isolated from Vaginal-Rectal Swabs. Infectious Diseases in Obstetrics and Gynecology, 2007, Article ID: 46581.

[63]   Morozumi, M., Wajima, T., Kuwata, Y., Chiba, N., Sunaoshi, K., Sugita, K., et al. (2014) Associations between Capsular Serotype, Multilocus Sequence Type, and Macrolide Resistance in Streptococcus agalactiae Isolates from Japanese Infants with Invasive Infections. Epidemiology and Infection, 142, 812-819.

[64]   Tazi, A., Morand, P.C., Reglier-Poupet, H., Dmytruk, N., Billoet, A., Antona, D., et al. (2011) Invasive Group B Streptococcal Infections in Adults, France (2007-2010). Clinical Microbiology and Infection, 17, 1587-1589.

[65]   Von Both, U. (2003) A Serotype V Clone Is Predominant among Erythromycin-Resistant Streptococcus agalactiae Isolates in a Southwestern Region of Germany. Journal of Clinical Microbiology, 41, 2166-2169.

[66]   Papasergi, S., Lanza Cariccio, V., Pietrocola, G., Domina, M., D’Aliberti, D., Trunfio, M.G., et al. (2013) Immunogenic Properties of Streptococcus agalactiae FbsA Fragments. PLoS ONE, 8, e75266.